CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 60 enrolled
Drug / intervention
L-Theanine +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00372151
NCT00372151Phase 3Completed
CompareCT.gov

The Value of Augmenting L-Theanine in the Management of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Sha'ar Menashe Mental Health Center·interventional·Posted Sep 6, 2006·Updated Dec 16, 2008

In Brief

A Phase 3 clinical trial evaluating L-Theanine and Placebo for Schizophrenia. Completed, enrolled 60 participants across 2 sites.

Detailed Summary

The aim of the proposed study is to investigate the efficacy and safety of add-on gamma-glutamylethylamide (L-theanine) versus a placebo for antipsychotic treatment for 8 weeks in a randomized, double-blind, parallel group study of 60 patients with schizophrenia and schizoaffective disorders.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSchizophrenia
CountriesIsrael
CollaboratorsStanley Medical Research Institute, Beersheva Mental Health Center

Timeline

Phase 3CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 6, 2006
Enrollment StartOct 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 19.8 years ago

Interventions

L-Theaninedietary

400 mg/day, caps.

Placeboother

caps.